Juergen Siepmann studied Pharmacy and did his Ph.D. at the Freie Universitaet Berlin, Germany. Since 2004 he is Professor of Pharmaceutical Technology at the University of Lille, France.
In 2006 Prof. Siepmann created the “Young research group: Controlled Drug Delivery Systems”, which became the “INSERM research group: Advanced Drug Delivery Systems” in 2010 (INSERM = French National Institute of Health and Medical Research). The team currently counts about 50 scientists: 9 professors, 6 senior lecturers, 7 technical/administrative staff, and about 20 post-docs/PhD students & 10 master students.
Prof. Siepmann’s research focuses on controlled drug delivery systems, in particular on the elucidation of the underlying mass transport phenomena, mathematical modeling and the optimization of the devices.
So far, he published his work in about 200 articles in international scientific journals, > 320 poster and > 140 oral presentations at national and international scientific meetings. He is editor of 3 books, theme editor of 10 special issues, inventor of 9 patents and author of 17 book chapters.
His awards include the “APV-Prize for the outstanding doctoral thesis in Pharmaceutical Sciences from the years 1998/99”, a Marie Curie Individual Post-Doctoral Fellowship and the “2012 APV Research Award for Outstanding Achievements in the Pharmaceutical Sciences”.
Prof. Siepmann was visiting scientist/postdoctoral fellow at Purdue University, the University of Paris-Sud, the University of Iowa and the University of Angers.
Since 2010 he serves as president of the “International Society of Drug Delivery Sciences and Technology” (“Association de Pharmacie Galénique Industrielle”, APGI). The APGI was created in 1964 in Paris, and is an association for scientists in academia and industry, who are concerned with pharmaceutical technology and the design, formulation as well as biopharmaceutical and pharmacokinetic assessment of dosage forms and drug delivery systems.
Prof. Siepmann also serves as Editor-in-Chief of the “International Journal of Pharmaceutics” (IJP) since 2016, publishing about 1000 research and reviews articles per year in the field of Pharmaceutical Technology and Drug Delivery. It’s 2019 impact factor is 4.8. It is a “top 1% journal” in the category “Pharmacology & Pharmacy” in terms of citation share (Web of Science, 2021). Since 2019, Prof. Siepmann also serves as Editor-in-Chief of the “International Journal of Pharmaceutics: X” (IJPX): the gold open access mirror journal of IJP.
Currently, Prof. Siepmann is also the coordinator of the Interreg project “Site Drug: Site-Specific Drug Delivery”. The consortium counts 10 European Universities and companies. The aim is to develop innovative drug delivery systems for improved local drug treatments.